

Cost-effectiveness Analysis (CEA) of Eladocagene Exuparvovec for Aromatic L-amino Acid Decarboxylase Deficiency (AADCd) and **Comparison With Other Rare Disease and One-time Treatments in the United States (US)**

Berrin Monteleone, MD;¹ Rongrong Zhang, MSc;² Paul Castellano, PharmD MBA;³ Thomas O'Connell, MA;⁴ Yixi Teng, MS;⁴ Ioannis Tomazos, PhD MBA³ ¹Department of Pediatrics, NYU Long Island School of Medicine; ²PTC Therapeutics Sweden AB, Askim, Sweden; ³PTC Therapeutics Inc, Warren, NJ, USA; ⁴Medicus Economics, Boston, MA, USA





Motor milestone	Multiples of MSD for total PDMS-2	Patient utilities	
NMF	0	-0.258	
FHC	1 (40 pts)	-0.155	
SU	2 (80 pts)	0.452	
SWS	3 (120 pts)	0.775	
WWA	4 (160 pts)	0.796	

FUNDING & DISCLOSURES: This study was funded by PTC Therapeutics, Inc. IT, PC, and RZ are employees of PTC Therapeutics and may own stocks in the company. TOC and YT are employees of Medicus Economics, which received funds from PTC to conduct this study. BM has received consulting fees from PTC and serves on an advisory board for Rett syndrome for Daybue. Medical writing support was provided by Broadstreet HEOR, and was funded by PTC Therapeutics.



	MOM			
DMS-2	MSM using MM achievement			
ncremental	EE	BSC	Incremental	
\$4,373,015	\$4,619,243	\$294,001	\$4,325,242	
\$4,275,809	\$4,380,734	\$137,760	\$4,242,974	
\$88,841	\$230,145	\$156,241	\$73,904	
\$8,365	\$8,365	\$0	\$8,365	
\$4,144,873	\$4,340,503	\$207,566	\$4,132,937	
\$4,125,777	\$4,212,752	\$96,693	\$4,116,059	
\$10,731	\$119,387	\$110,873	\$8,514	
\$8,365	\$8,365	\$0	\$8,365	

S-2	MSM using MM achievement			
mental	EE	BSC	Incremental	
5.24	48.27	18.24	30.03	
3.87	26.06	-12.31	38.36	
,682			\$112,744	
.85	22.98	12.75	10.22	
.83	10.13	-8.31	18.44	
9,007			\$224,104	



1.	Wassenberg T, Molero-Luis M, Jeltsch K, et al. Orphanet J F
2.	Pearson TS, Gilbert L, Opladen T, et al. J Inherit Metab Dis.
3.	U.S. Food & Drug Administration. FDA Approves First Gene
	events/press-announcements/fda-approves-first-gene-thera
4.	Bergkvist M, Stephens C, Schilling T, et al. Future Neurology
5.	Tai, Chun-Hwei et al. Molecular Therapy, Volume 30, Issue 2
6.	Brooks JC, Strauss DJ, Shavelle RM, Tran LM, Rosenbloom
7.	Landfeldt E, Lindgren P, Bell CF, et al. J Neurol. 2016;263(5
8.	Song J, Floyd FJ, Seltzer MM, Greenberg JS, Hong J. 2010
0	Huu WI Loo H M Doinort ID at al Ornhanot / Para Dia

- 11. Institute for Clinical and Economic Review. Assessments [Available from: https://icer.org/explore-our-research/assessments/] 12. Hwu WL, Hsu RH, Li MH, et al. JIMD reports. 2023; 64(5), 387-392.



© 2025 PTC Therapeutics, Inc. All rights reserved